Global Amitriptyline Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 607.0 Million in 2023 and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
An increase in the prevalence of mental disorders such as depression, anxiety, and others is expected to drive the market growth during the forecast period. For instance, according to data published by the Centers of Disease Control and Prevention (CDC), on June 16, 2023, depression is a major contributor to mortality, morbidity, disability, and economic costs in the U.S., with more than 18.4% of U.S. adults diagnosed with depression in 2020.
Global Amitriptyline Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively.
However, COVID-19 pandemic had a positive impact on global amitriptyline market, as, due to COVID-19, there a sudden increase in the number of mental disorders. This is expected to have positive impact on the market. For instance, according to an article published by World Health Organization, in March 2022, it is estimated, that the COVID-19 pandemic has led to a 27.6% increase in cases of major depressive disorder (MDD), and a 25.6% increase in cases of anxiety disorders (AD) worldwide, in 2020.
Global Amitriptyline Market: Key Developments
On March 14, 2023, AlgoTx, a France-based clinical stage biotechnology company, announced that it had raised US$ 22 million (€20M) Series B fundraising from TURENNE GROUPE, a capital market company
Browse 37 Market Data Tables and 36 Figures spread through 180 Pages and in-depth TOC on “Global Amitriptyline Market”- Forecast to 2030, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/amitriptyline-market-4226
Key Takeaways of the Global Amitriptyline Market:
- The global amitriptyline market is expected to exhibit a CAGR of 5.6% during the forecast period due to the increase in the number of research and development activities by key market players. For instance, ATX01, a drug candidate by AlgoTherapeutix, a France-based clinical stage biotechnology company, is currently in phase-II of clinical trials, which has been tested for treatment of Erythromelalgia, a rare condition that causes episodes of burning, pain, and redness in the feet and hands.
- Among strength, 10 mg tablets segment is estimated to hold a dominant position in the global amitriptyline market over the forecast period, owing to the advantages and uses of amitryptiline, such as, it is a mood elevator, it is use to treat insomnia, depression, and mental disorder.
- Among indication, the deperssion segment is estimated to hold a dominant position in global amitriptyline over the forecast period, as it approved by S. FDA, for treatment of depression in adults.
- Major players operating in the global amitriptyline market, includes Accord Healthcare Inc., Viatris Inc., Sandoz Inc., Sun Pharmaceutical Industries , Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., Torrent Pharmaceuticals Ltd., Dr Reddy's Laboratories Ltd., Unichem Laboratories Ltd., Apotex Inc. and Intas Pharmaceuticals Ltd.
